Thera-SAbDab: the therapeutic structural antibody database
Open accessPublished version of a preprint
Abstract
The Therapeutic Structural Antibody Database (Thera-SAbDab; http://opig.stats.ox.ac.uk/webapps/therasabdab) tracks all antibody- and nanobody-related therapeutics recognized by the World Health Organisation (WHO), and identifies any corresponding structures in the Structural Antibody Database (SAbDab) with near-exact or exact variable domain sequence matches. Thera-SAbDab is synchronized with SAbDab to update weekly, reflecting new Protein Data Bank entries and the availability of new sequence data published by the WHO. Each therapeutic summary page lists structural coverage (with links to the appropriate SAbDab entries), alignments showing where any near-matches deviate in sequence, and accompanying metadata, such as intended target and investigated conditions. Thera-SAbDab can be queried by therapeutic name, by a combination of metadata, or by variable domain sequence - returning all therapeutics that are within a specified sequence identity over a specified region of the query. The sequences of all therapeutics listed in Thera-SAbDab (461 unique molecules, as of 5 August 2019) are downloadable as a single file with accompanying metadata.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
As of July 2022, Thera-SAbDab is tracking 748 unique therapeutics, including monoclonal antibody and bispecific therapeutics.
“As of July 2022, this database is tracking 748 unique therapeutics, including monoclonal antibody and bispecific therapeutics.”
From Computational and artificial intelligence-based methods for antibody development (2023) · cites this paper as [15]
Thera-SAbDab is a therapeutic structural antibody database including antibody- and nanobody-related biotherapeutics.
“Additionally, the Therapeutic Structural Antibody Database (Thera-SAbDab) is a therapeutic structural antibody database including antibody-and nanobodyrelated biotherapeutics [15].”
From Computational and artificial intelligence-based methods for antibody development (2023) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196 · see citing works
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271 · cited 1× · see citing works
“These fragments can be expressed in dimeric form to improve avidity, or conjugated with polyethylene glycol (‘pegylated’) for slower clearance (4), with radioisotopes for diagnostic purposes (5), or with radioisotopes or noxious small molecules/peptides for cytotoxicity (6).”
BackgroundBispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303 · cited 1× · see citing works
“As of June 2019, bispecific mAbs, linked Fabs, linked scFvs and linked single-domain variable fragments have all been assessed in clinical trials (7).”
BackgroundStandard conformations for the canonical structures of immunoglobulins 1 1Edited by I. A. Wilson
Al‐Lazikani, B., Lesk, A. M., & Chothia, C. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1354 · Cited by 707 · see citing works
SAbDab: the structural antibody database
Dunbar, J., Krawczyk, K., Leem, J., Baker, T., Fuchs, A., Georges, G., Shi, J., & Deane, C. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1043 · Cited by 674 · cited 2× · see citing works
“A significant fraction of these structures contain antibody variable domains, and these are recorded by the Structural Antibody Database (SAbDab (16); 7184 variable domain structures over 3663 PDB entries as of 5 August 2019).”
BackgroundThe Increasingly Human and Profitable Monoclonal Antibody Market
Grilo, A. L., & Mantalaris, A. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.014 · Cited by 468 · see citing works
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 462 · see citing works
Kaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 435 · cited 1× · see citing works
“Whole monoclonal antibody (mAb) therapies dominate the industry - drugs that mimic natural antibodies by containing two identical variable domain structures with a particular specificity (3).”
BackgroundANARCI: antigen receptor numbering and receptor classification
Dunbar, J., & Deane, C. M. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv552 · Cited by 421 · cited 3× · see citing works
“We harvest sequences as they are released by the WHO, number them with ANARCI (17), and perform a weekly sequence alignment of all therapeutic variable domain sequences to the sequences of known structures stored in SAbDab.”
BackgroundMethodInfluentialHomology modeling in drug discovery: Overview, current applications, and future perspectives
Muhammed, M. T., & Aki, E. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13388 · Cited by 367 · cited 1× · see citing works
“It can also assist subsequent development and optimization, as homology models of mutants derived from a known structure are in general more accurate than those for which no close structural partner is available (14).”
BackgroundFive computational developability guidelines for therapeutic antibody profiling
Raybould, M. I. J., Marks, C., Krawczyk, K., Taddese, B., Nowak, J., Lewis, A. P., Bujotzek, A., Shi, J., & Deane, C. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810576116 · Cited by 357 · cited 2× · see citing works
“Links to appropriate SAbPred (21) informatics tools (such as ABodyBuilder (22) for variable domain structure modelling, and TAP (18) for developability assessment) are also provided.”
BackgroundMethodABodyBuilder: automated antibody structure prediction with data-driven accuracy estimation
Leem, J., Dunbar, J., Georges, G., Shi, J., & Deane, C. M. (2016) · mAbs · doi:10.1080/19420862.2016.1205773 · Cited by 238 · cited 1× · see citing works
“Links to appropriate SAbPred (21) informatics tools (such as ABodyBuilder (22) for variable domain structure modelling, and TAP (18) for developability assessment) are also provided.”
MethodSAbPred: a structure-based antibody prediction server
Dunbar, J., Krawczyk, K., Leem, J., Marks, C., Nowak, J., Regep, C., Georges, G. J., Kelm, S., Popovic, B., & Deane, C. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw361 · Cited by 202 · cited 1× · see citing works
“Links to appropriate SAbPred (21) informatics tools (such as ABodyBuilder (22) for variable domain structure modelling, and TAP (18) for developability assessment) are also provided.”
MethodAntibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Steiner, M., & Neri, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0483 · Cited by 157 · cited 1× · see citing works
“These fragments can be expressed in dimeric form to improve avidity, or conjugated with polyethylene glycol (‘pegylated’) for slower clearance (4), with radioisotopes for diagnostic purposes (5), or with radioisotopes or noxious small molecules/peptides for cytotoxicity (6).”
BackgroundStructure-based drug design: aiming for a perfect fit
van Montfort, R. L. M., & Workman, P. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170052 · Cited by 127 · cited 1× · see citing works
“Structural knowledge about both the intended target and the therapeutic lead compound is of high importance for rational drug discovery (12,13).”
BackgroundThe ABCD database: a repository for chemically defined antibodies
de Lima, W. C., Gasteiger, E., Marcatili, P., Duek, P. D., Bairoch, A., & Cosson, P. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz714 · Cited by 70 · cited 1× · see citing works
“For example, the recently published ABCD database provides antibody synonyms, antigen UniProt links and publication references (11).”
BackgroundBenschop, R. J., Chow, C.-K., Tian, Y., Nelson, J., Barmettler, B., Atwell, S., Clawson, D. K., Chai, Q., Jones, B. E., Fitchett, J. R., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1624463 · Cited by 53 · cited 12× · see citing works
“A significant fraction of these structures contain antibody variable domains, and these are recorded by the Structural Antibody Database (SAbDab (16); 7047 variable domain structures over 3620 PDB entries as of 18th July 2019).”
BackgroundInfluentialPEGylation of Antibody Fragments for Half-Life Extension
Jevševar, S., Kusterle, M., & Kenig, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-931-0_15 · Cited by 38 · see citing works
Antibody–antigen complex modelling in the era of immunoglobulin repertoire sequencing
Raybould, M. I. J., Wong, W. K., & Deane, C. M. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00034h · Cited by 14 · cited 1× · see citing works
“Structural knowledge about both the intended target and the therapeutic lead compound is of high importance for rational drug discovery (12,13).”
Background
Flagged first, then by citations
Research works printed but not linked: 3
- [8]WHO Proposed International Nonproprietary Names (INN) List 120. WHO Drug Information. 2018; 32: 559– 689.
- [9]WHO Recommended International Nonproprietary Names (INN) List 81. WHO Drug Information. 2019; 33: 59– 134.
- [10]Poiron C., Wu Y., Ginestoux C., Ehrenmann F., Duroux P., Lefranc M.-P. IMGT/mAb-DB: the IMGT database for therapeutic monoclonal antibodies. JOBIM 2010. 2010; 13: 470b.
Cited by
Sorted by citations
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chao, H., Chen, L., Craig, P., Crichlow, G. V., Dalenberg, K., Duarte, J. M., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1077 · Cited by 903 · see citing works
“Thera-SAbDab (94) Therapeutic Structural Antibody Database”
Efficient evolution of human antibodies from general protein language models
Hie, B., Shanker, V. R., Xu, D., Bruun, T. U. J., Weidenbacher, P. A. B., Tang, S., Wu, W. C. H., Pak, J. E., & Kim, P. S. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01763-2 · Cited by 444 · see citing works
“We downloaded 742 therapeutically relevant antibodies from the Thera-SAbDab database as of 26 February 2022 (http://opig.stats. ox.ac.uk/webapps/newsabdab/therasabdab/) 47 .”
Prihoda, D., Maamary, J., Waight, A., Juan, V., Fayadat-Dilman, L., Svozil, D., & Bitton, D. A. (2022) · mAbs · doi:10.1080/19420862.2021.2020203 · Cited by 190 · see citing works
“Recovering 152 putative parental sequences Records with “-zumab” suffix were collected from TheraSAbDab, totaling 164 humanized therapeutics.”
MethodComputational and artificial intelligence-based methods for antibody development
Kim, J., McFee, M., Fang, Q., Abdin, O., & Kim, P. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.005 · Cited by 178 · see citing works
IgLM: Infilling language modeling for antibody sequence design
Shuai, R. W., Ruffolo, J. A., & Gray, J. J. (2023) · Cell Systems · doi:10.1016/j.cels.2023.10.001 · Cited by 165 · see citing works
SAbDab in the age of biotherapeutics: updates including SAbDab-nano, the nanobody structure tracker
Schneider, C., Raybould, M. I. J., & Deane, C. M. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1050 · Cited by 154 · see citing works
“A large body of research has now been published on their properties and their potential as therapeutics (8,9), including for SARS-CoV-2 (10).”
BackgroundInfluentialBurley, S. K., Berman, H. M., Duarte, J. M., Feng, Z., Flatt, J. W., Hudson, B. P., Lowe, R., Peisach, E., Piehl, D. W., Rose, Y., et al. (2022) · Biomolecules · doi:10.3390/biom12101425 · Cited by 144 · see citing works
Humanization of antibodies using a machine learning approach on large-scale repertoire data
Marks, C., Hummer, A. M., Chin, M., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab434 · Cited by 124 · see citing works
“Whilst multiple techniques have been developed to obtain fully human mAbs, humanized antibodies remain the predominant class of mAb making up 50% of therapeutics in development (3).”
BackgroundMethodInfluentialRCSB Protein Data bank: Tools for visualizing and understanding biological macromolecules in 3D
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chao, H., Chen, L., Craig, P., Crichlow, G. V., Dalenberg, K., Duarte, J. M., et al. (2022) · Protein Science · doi:10.1002/pro.4482 · Cited by 119 · see citing works
Akbar, R., Bashour, H., Rawat, P., Robert, P. A., Smorodina, E., Cotet, T., Karlsen, K. F., Frank, R., Mehta, B. B., Vu, M. H., et al. (2022) · mAbs · doi:10.1080/19420862.2021.2008790 · Cited by 117 · see citing works
Advances in computational structure-based antibody design
Hummer, A. M., Abanades, B., & Deane, C. M. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102379 · Cited by 105 · see citing works
NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning
Cohen, T., Halfon, M., & Schneidman‐Duhovny, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958584 · Cited by 91 · see citing works
“The antibody structures were obtained from abYbank/AbDb (53) and SAbDab (54, 55); a total of 2,085 non-redundant structures of Nbs (319) and mAb heavy chains (1,766) were used.”
MethodGreiff, V., Yaari, G., & Cowell, L. G. (2020) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2020.10.010 · Cited by 87 · see citing works
Khuat, T. T., Bassett, R., Otte, E. A., Grevis-James, A., & Gabryś, B. (2024) · Computers & Chemical Engineering · doi:10.1016/j.compchemeng.2024.108585 · Cited by 98 · see citing works
Khetan, R., Curtis, R., Deane, C. M., Hadsund, J. T., Kar, U., Krawczyk, K., Kuroda, D., Robinson, S. A., Sormanni, P., Tsumoto, K., et al. (2022) · mAbs · doi:10.1080/19420862.2021.2020082 · Cited by 86 · see citing works
“14 The Jain dataset provides biophysical characterization across 12 different platforms for 137 clinical-stage and approved antibodies.”
The 27th annual Nucleic Acids Research database issue and molecular biology database collection
Rigden, D. J., & Fernández, X. M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1161 · Cited by 74 · see citing works
“Another valuable new database relating to antibodies Thera-SAbDab (21) links therapeutic antibody or nanobody sequences recognized by the World Health Organisation to entries in the authors’ structural antibody database SAbDab (22) for similar or identical proteins.”
BackgroundADCdb: the database of antibody–drug conjugates
Shen, L., Sun, X., Chen, Z., Guo, Y., Shen, Z., Song, Y., Xin, W., Ding, H., Ma, X., Xu, W., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad831 · Cited by 75 · see citing works
“…aim at describing the particular components of each ADC, which include (a) those offering mAb moiety, such as: IMGT / mAb-DB ( 10 ), Thera-SAbDab ( 11 ) and PDB ( 12 ), and (b) those showing the physicochemical properties of either linkers or payloads, such as: PubChem ( 13 ) and DrugCentral ( 14…”
BackgroundAssessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV
Ramon, A., Ali, M., Atkinson, M., Saturnino, A., Didi, K., Visentin, C., Ricagno, S., Xu, X., Greenig, M., & Sormanni, P. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-023-00778-3 · Cited by 80 · see citing works
“44, and three therapeutic nanobody sequences (envafolimab, caplacizumab and rimteravimab) available from the therapeutic database Thera-SAbDab 79 .”
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 76 · see citing works
“The following sections describe the system-wise utilization or application of antibody therapeutics in treating diseases in different branches of medicine, ranging from hematology, oncology, and autoimmune disease to different organ system-related disorders like vascular, renal, neurological, etc.”
BackgroundJain, T. S., Boland, T., & Vásquez, M. (2023) · mAbs · doi:10.1080/19420862.2023.2200540 · Cited by 73 · see citing works
Addressing the antibody germline bias and its effect on language models for improved antibody design
Olsen, T. H., Moal, I. H., & Deane, C. M. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae618 · Cited by 70 · see citing works
SYNBIP: synthetic binding proteins for research, diagnosis and therapy
Wang, X., Li, F., Qiu, W., Xu, B., Li, Y., Lian, X., Yu, H., Zhang, Z., Wang, J., Li, Z., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab926 · Cited by 69 · see citing works
How repertoire data are changing antibody science
Marks, C., & Deane, C. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.010181 · Cited by 68 · see citing works
Automated optimisation of solubility and conformational stability of antibodies and proteins
Rosace, A., Bennett, A., Oeller, M., Mortensen, M. M., Sakhnini, L. I., Lorenzen, N., Poulsen, C., & Sormanni, P. (2023) · Nature Communications · doi:10.1038/s41467-023-37668-6 · Cited by 65 · see citing works
“…antibody or nanobody, the user can choose between a set of pre-compiled alignments of species-specific antibodies (human or mouse), or therapeutic antibodies (post phase-I clinical trial) (57, 58), or single-domain antibodies obtained from multiple camelid species (59) (see Supplementary Methods).”
BackgroundPuranik, A., Dandekar, P. P., & Jain, R. D. (2022) · Biotechnology Progress · doi:10.1002/btpr.3291 · Cited by 63 · see citing works
Dewaker, V., Morya, V. K., Kim, Y. H., Park, S. T., Kim, H. S., & Koh, Y. H. (2025) · Biomarker Research · doi:10.1186/s40364-025-00764-4 · Cited by 59 · see citing works
Boughter, C. T., Borowska, M. T., Guthmiller, J. J., Bendelac, A. S., Wilson, P. C., Roux, B., & Adams, E. J. (2020) · eLife · doi:10.7554/elife.61393 · Cited by 56 · see citing works
Grinshpun, B., Thorsteinson, N., Pereira, J. N., Rippmann, F., Nannemann, D., Sood, V. D., & Fomekong Nanfack, Y. (2021) · mAbs · doi:10.1080/19420862.2021.1932230 · Cited by 52 · see citing works
“At the time this work was conducted, there were 75 approved mAbs and over 200 in Phases 2 and 3 undergoing clinical trials.(20,21)”
BackgroundAntibody design using deep learning: from sequence and structure design to affinity maturation
Joubbi, S., Micheli, A., Milazzo, P., Maccari, G., Ciano, G., Cardamone, D., & Medini, D. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae307 · Cited by 54 · see citing works
“Additional resources, such as the Antibody Structure Database (AbDb) [37], abYsis [36] and the Therapeutic Structural Antibody Database (Thera-SAbDab) [50], are listed in Table 1.”
BackgroundComparison of hydrophobicity scales for predicting biophysical properties of antibodies
Waibl, F., Fernández‐Quintero, M. L., Wedl, F. S., Kettenberger, H., Georges, G. J., & Liedl, K. R. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.960194 · Cited by 46 · see citing works
“, 2022) with more than 120 approved therapeutic antibodies up to now (Raybould et al., 2020).”
BackgroundAbanades, B., Olsen, T. H., Raybould, M. I. J., Aguilar-Sanjuan, B., Wong, W. K., Georges, G. J., Bujotzek, A., & Deane, C. M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1056 · Cited by 46 · see citing works
Prospects for the computational humanization of antibodies and nanobodies
Gordon, G. L., Raybould, M. I. J., Wong, A., & Deane, C. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399438 · Cited by 47 · see citing works
“However, these efforts are hampered by the fact that nanobody data are currently relatively limited and dispersed (Table 2, 4, 54, 55, 94).”
BackgroundRaybould, M. I. J., Turnbull, O. M., Suter, A., Guloglu, B., & Deane, C. M. (2024) · Communications Biology · doi:10.1038/s42003-023-05744-8 · Cited by 44 · see citing works
“To assess the properties of CSTs over time, we split the set by the year they were given a proposed WHO International Non-proprietary Name, yielding 356 named between 1987 – 2017 and 308 named between 2018 and the present day.”
InfluentialA perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies
de Graaf, S. C., Hoek, M., Tamara, S., & Heck, A. J. R. (2022) · mAbs · doi:10.1080/19420862.2022.2079449 · Cited by 43 · see citing works
“first therapeutic antibody was registered in 1986, and this advent launched large-scale development of mAbs, with a hundred mAbs in advanced stage of development by 2008.(4) At that point, next-generation sequencing led to high-throughput sequencing workflows and further facilitated the development of therapeutic anti…”
BackgroundZero-shot antibody design in a 24-well platePreprint
Chai Discovery Team, Boitreaud, J., Dent, J., Geisz, D., McPartlon, M., Meier, J., Qiao, Z., Rogozhnikov, A., Rollins, N., Wollenhaupt, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.05.663018 · Cited by 49 · see citing works
Thorsteinson, N., Gunn, J. R., Kelly, K., Long, W., & Labute, P. (2021) · mAbs · doi:10.1080/19420862.2021.1981805 · Cited by 42 · see citing works
Nanobodies: From Discovery to AI-Driven Design
Zhu, H., & Ding, Y. (2025) · Biology · doi:10.3390/biology14050547 · Cited by 43 · see citing works
“Despite the apparent breakthroughs described above, it should be noted that the scarcity of publicly available nanobody humanization models and the relatively limited and dispersed nature of nanobody data [197–200] still hinder the development of new computational methods.”
Wilkinson, I. C., & Hale, G. (2022) · mAbs · doi:10.1080/19420862.2022.2123299 · Cited by 38 · see citing works
Immunotherapeutic targeting of surfaceome heterogeneity in AML
Bordeleau, M.-È., Audemard, E. O., Métois, A., Thérêt, L., Lisi, V., Farah, A., Spinella, J.-F., Chagraoui, J., Moujaber, O., Aubert, L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114260 · Cited by 37 · see citing works
Richardson, E., Galson, J. D., Kellam, P., Kelly, D. F., Smith, S. E., Palser, A. L., Watson, S. J., & Deane, C. M. (2021) · mAbs · doi:10.1080/19420862.2020.1869406 · Cited by 38 · see citing works
“An antibody is flagged as "red" if the value of a particular metric is outside of the observed range in CSTs. [38] 5 Funding The”
MethodInfluentialComputational optimization of antibody humanness and stability by systematic energy-based ranking
Tennenhouse, A., Khmelnitsky, L., Khalaila, R., Yeshaya, N., Noronha, A., Lindzen, M., Makowski, E. K., Zaretsky, I., Sirkis, Y. F., Galon-Wolfenson, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01079-1 · Cited by 37 · see citing works
“Antibodies are the largest segment of protein-based therapeutics, with over 100 antibodies in clinical use or under regulatory review 1 .”
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue
Irudayanathan, F. J., Zarzar, J., Lin, J., & Izadi, S. (2022) · mAbs · doi:10.1080/19420862.2022.2143006 · Cited by 34 · see citing works
“uk/webapps/newsabdab/ sabdab/).(58,59) We arrived at 3493 structures, which were then cleaned, energy minimized and isolated from any other ligands.”
BackgroundPark, E., & Izadi, S. (2024) · mAbs · doi:10.1080/19420862.2024.2362788 · Cited by 32 · see citing works
“28,85 For descriptors in which extremely large values are less desirable (e.g. CDR_HPATCH_BM, CDR_HPATCH_WW, CDR_APBS_pos, CDR_len), the 90th and 95th percentiles of the distributions serve as the thresholds to define medium risk (amber) and high risk (red) flags, respectively.”
BackgroundLearning the language of antibody hypervariability
Singh, R., Im, C., Qiu, Y., Mackness, B. C., Gupta, A., Joren, T., Sledzieski, S., Erlach, L., Wendt, M., Fomekong‐Nanfack, Y., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2418918121 · Cited by 44 · see citing works
“Towards that, we mapped 547 antibodies from Thera-SABDab, a dataset of immunotherapeutic antibodies that have entered clinical trials ( 40 ).”
Bashour, H., Smorodina, E., Pariset, M., Zhong, J., Akbar, R., Chernigovskaya, M., Lê Quý, K., Snapkow, I., Rawat, P., Krawczyk, K., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06561-3 · Cited by 32 · see citing works
“A total of 782 therapeutic antibody sequences belonging to the “ whole mAb ” format were obtained from TheraSAbDAb as per July 2021 139 .”
nanoBERT: a deep learning model for gene agnostic navigation of the nanobody mutational space
Hadsund, J. T., Satława, T., Janusz, B., Shan, L., Zhou, L. Y., Röttger, R., & Krawczyk, K. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbae033 · Cited by 30 · see citing works
“As the therapeutic test set we compiled a list of 18 therapeutic nanobodies from public sources (Raybould et al. 2020, Deszy � nski et al. 2022).”
BackgroundRaybould, M. I. J., Marks, C., Kovaltsuk, A., Lewis, A. P., Shi, J., & Deane, C. M. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008781 · Cited by 29 · see citing works
“The set of 89 therapeutics with 100% sequence identical structures (as of November 2019) were retrieved from Thera-SAbDab [36].”
MethodInfluentialMorales, I. C., Dingfelder, F., Waibel, I., Turnbull, O. M., Patel, B., Cao, Z., Bjelke, J. R., Grell, S. N., Bennet, A., Hummer, A. M., et al. (2024) · mAbs · doi:10.1080/19420862.2024.2403156 · Cited by 27 · see citing works
The therapeutic antibody profiler for computational developability assessment
Raybould, M. I. J., & Deane, C. M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1450-1_5 · Cited by 25 · see citing works
Data mining patented antibody sequences
Krawczyk, K., Buchanan, A. G., & Marcatili, P. (2021) · mAbs · doi:10.1080/19420862.2021.1892366 · Cited by 25 · see citing works
Negron, C., Fang, J., McPherson, M. J., Stine, W. B., & McCluskey, A. J. (2022) · mAbs · doi:10.1080/19420862.2022.2080628 · Cited by 24 · see citing works
“24 These sequences represent antibodies that are either approved, underwent clinical evaluation, or are currently being evaluated in the clinic.”
BackgroundAlphaFold3, a secret sauce for predicting mutational effects on protein-protein interactionsPreprint
Lu, W., Zhang, J., Rao, J., Zhang, Z., & Zheng, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.25.595871 · Cited by 27 · see citing works
“Most antibody drugs in clinical use have picomolar affinity for the target protein [12], while antibodies found through immunization commonly exhibit affinities in the nanomolar or even micromolar range [13].”
BackgroundEvers, A., Guarnera, E., Pekar, L., & Zielonka, S. (2025) · mAbs · doi:10.1080/19420862.2025.2583210 · Cited by 21 · see citing works
PPB-Affinity: Protein-Protein Binding Affinity dataset for AI-based protein drug discovery
Liu, H., Chen, P., Zhai, X., Huo, K.-G., Zhou, S., Han, L., & Fan, G. (2024) · Scientific Data · doi:10.1038/s41597-024-03997-4 · Cited by 24 · see citing works
Yu, M., Shi, Z., Zhang, W., Zhu, L. D., Tang, S., Chen, H., Wang, X., Du, Q., Li, S. C., Zhang, Y., et al. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200134 · Cited by 18 · see citing works
“Then, we aligned the CDR3 amino acid sequences of clonotype1 to the SAbDab antibody data-base, 42 revealing similarities to CMV-related antibodies (eFigure 9C, links.lww.com/NXI/A872).”
MethodIsAb: a computational protocol for antibody design
Liang, T., Chen, H., Yuan, J., Jiang, C., Hao, Y., Wang, Y., Feng, Z., & Xie, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab143 · Cited by 17 · see citing works
“Another powerful database is SAbDab [65, 66], which contains antibodies data and modeling function.”
BackgroundRichardson, E., Binter, Š., Kosmač, M., Ghraichy, M., von Niederhäusern, V., Kovaltsuk, A., Galson, J. D., Trück, J., Kelly, D. F., Deane, C. M., et al. (2023) · eLife · doi:10.7554/elife.81629 · Cited by 16 · see citing works
“The amino acid sequences of these heavy chains can also be functionally examined through annotation with structural tools ( Kovaltsuk et al., 2017 ; Marks and Deane, 2020 ).”
BackgroundAB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains
Zhou, Y., Huang, Z., Gou, Y., Liu, S., Yang, W., Zhang, H., Dzisoo, A. M., & Huang, J. H. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad007 · Cited by 16 · see citing works
“These LC sequences were extracted from “The Therapeutic Structural Antibody Database” (Thera-SAbDab) [29] and cleaned as above.”
Fast and accurate modeling and design of antibody-antigen complex using tFoldPreprint
Wu, F., Zhao, Y. S., Wu, J., Jiang, B., He, B., Huang, L.-K., Qin, C., Yang, F., Huang, N., Xiao, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.05.578892 · Cited by 16 · see citing works
De novo design of epitope-specific antibodies via a structure-driven computational workflow
Wu, F., Zhao, Y. S., Wu, J., Jiang, B., He, B., Huang, L.-K., Qin, C., Xiao, Y., Yang, F., Wang, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67361-9 · Cited by 18 · see citing works
“It comprises: (cid:129) 27 anti-PD-1 therapeutic antibodies curated from Thera-SAbDab 37 (WHO-listed therapeutics with publicly available sequences).”
Advances in antibody discovery from human BCR repertoires
Xu, Z., Ismanto, H. S., Zhou, H., Saputri, D. S., Sugihara, F., & Standley, D. M. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.1044975 · Cited by 15 · see citing works
“As of 19 July 2022, there were only 9,811 recorded antibodyantigen structures available in the Protein Data Bank (Berman et al., 2008; Raybould et al., 2020).”
BackgroundLarge-scale computational modelling of H5 influenza variants against HA1-neutralising antibodies
Ford, C. T., Yasa, S., Obeid, K., Jaimes, R., Tomezsko, P. J., Guirales-Medrano, S., White, R. A., III, & Janies, D. A. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105632 · Cited by 15 · see citing works
Therapeutic Antibodies: An Overview
Houen, G. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1450-1_1 · Cited by 15 · see citing works
Learning the Language of Antibody HypervariabilityPreprint
Singh, R., Im, C., Qiu, Y., Mackness, B. C., Gupta, A., Sorenson, T., Sledzieski, S., Erlach, L., Wendt, M., Fomekong‐Nanfack, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.26.538476 · Cited by 16 · see citing works
PLAbDab-nano: a database of camelid and shark nanobodies from patents and literature
Gordon, G. L., Greenshields‐Watson, A., Agarwal, P., Wong, A., Boyles, F., Hummer, A. M., Hernandez, A. G. L., & Deane, C. M. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae881 · Cited by 13 · see citing works
Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies
Rawat, P., Sharma, D., Srivastava, A., Vani, J., & Gromiha, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-89621-6 · Cited by 13 · see citing works
KA-Search, a method for rapid and exhaustive sequence identity search of known antibodies
Olsen, T. H., Abanades, B., Moal, I. H., & Deane, C. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-38108-7 · Cited by 12 · see citing works
“As our canonical alignment, we use all of the 196 unique positions seen in at least 40,000 different sequences in OAS, as of May 2022, and four additional unique positions seen in therapeutics from Thera-SAbDab 43 .”
BackgroundMethodDOTAD: A Database of Therapeutic Antibody Developability
Li, W., Lin, H., Huang, Z., Xie, S., Zhou, Y., Gong, R., Jiang, Q., Xiang, C., & Huang, J. H. (2024) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-024-00613-2 · Cited by 12 · see citing works
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains
Chinery, L., Jeliazkov, J. R., & Deane, C. M. (2024) · mAbs · doi:10.1080/19420862.2024.2434121 · Cited by 12 · see citing works
“3 found that approximately 60% of therapeutics listed in Thera-SAbDab 4 are not genetically human in origin and that this percentage has remained constant over the past two decades.”
Martí, D., Alsina, M., Alemán, C., Bertrán, O., Turón, P., & Torras, J. (2021) · Biochimie · doi:10.1016/j.biochi.2021.10.013 · Cited by 12 · see citing works
“The positions of the residues belonging to the CDRs are labeled according to the Kabat numbering scheme and obtained from SabDab structural antibody database [71,72].”
Li, Y., Li, F., Duan, Z., Liu, R., Jiao, W., Wu, H., Zhu, F., & Xue, W. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae893 · Cited by 11 · see citing works
Seidler, C. A., Spanke, V. A., Gamper, J., Bujotzek, A., Georges, G. J., & Liedl, K. R. (2025) · mAbs · doi:10.1080/19420862.2025.2507950 · Cited by 11 · see citing works
“In this figure, the distribution of therapeutic antibodies that are listed in Thera-SAbDab 32 (20.12.2024) and are either currently in clinical trials (Phase 1, 2, or 3) or approved are shown over the OAS distribution.”
InfluentialImmunoMatch learns and predicts cognate pairing of heavy and light immunoglobulin chains
Guo, D., Dunn‐Walters, D. K., Fraternali, F., & Ng, J. C.-F. (2025) · Nature Methods · doi:10.1038/s41592-025-02913-x · Cited by 11 · see citing works
Ojha, R., Gurjar, K., Ratnakar, T. S., Mishra, A., & Prajapati, V. K. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.01.004 · Cited by 11 · see citing works
A generative foundation model for antibody sequence understandingPreprint
Barton, J., Gaspariunas, A., Yadin, D., Dias, J., Nice, F. L., Minns, D., Snudden, O., Povall, C., Valle, S., Dobson, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.22.594943 · Cited by 11 · see citing works
“TAP profiles were measured using the online version of TAP.”
BackgroundMethodInfluentialA comprehensive antigen-antibody complex database unlocking insights into interaction interfacePreprint
Zhou, Y., Liu, W., Huang, Z., Gou, Y., Liu, S., Jiang, L., Yang, Y., & Huang, J. H. (2025) · eLife · doi:10.7554/elife.104934 · Cited by 11 · see citing works
Antibody numbering schemes: advances, comparisons and tools for antibody engineering
Zhu, Z., Ashrafian, H., Mohammadian-Tabrizi, N., Matas, E. R., Girard, L., Ma, H., & Nice, E. C. (2025) · Protein Engineering Design and Selection · doi:10.1093/protein/gzaf005 · Cited by 10 · see citing works
Rodrigues, C. H. M., & Ascher, D. B. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26615 · Cited by 9 · see citing works
Exploring Bioinformatics Solutions for Improved Leishmaniasis Diagnostic Tools: A Review
Costa, N. T. C., Pereira, A. M. D. S., da Silva, C. M., Souza, E., Ferreira, L. F., de Oliveira, B., Hernandes, M. Z., & Pereira, V. R. A. (2024) · Molecules · doi:10.3390/molecules29225259 · Cited by 9 · see citing works
“The Structural Antibody Database (SAbDab) is a web tool (available: https://opig. stats.ox.ac.uk/webapps/sabdab) database of antibody structures that has over 6000 antibody structures [99].”
MethodPredicting purification process fit of monoclonal antibodies using machine learning
Maier, A. J., Cha, M., Burgess, S., Wang, A., Cuellar, C., Kim, S. Y., Rajan, N. S., Neyyan, J., SENGUPTA, R., O’Connor, K., et al. (2025) · mAbs · doi:10.1080/19420862.2024.2439988 · Cited by 11 · see citing works
“While the full sequences of clinical stage mAbs are not publicly available, Fv sequences are collated in the Therapeutic Structural Antibody Database 68 (Thera-SAbDab).”
BackgroundIMGT® at scale: FAIR, dynamic, and automated tools for immune locus analysis
Sanou, G., Zeitoun, G., Manso, T., Eidi, M., Batool, S., Kushwaha, A., Grand, F., Croze, M., Vaillant, A., Debbagh, C., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1024 · Cited by 9 · see citing works
Singh, S., Rao, A., Mishra, A., Mishra, A., & Prajapati, V. K. (2023) · Molecular Systems Design & Engineering · doi:10.1039/d3me00059a · Cited by 9 · see citing works
YAbS: The Antibody Society’s antibody therapeutics database
Rawat, P., Crescioli, S., Prabakaran, R., Sharma, D., Greiff, V., & Reichert, J. M. (2025) · mAbs · doi:10.1080/19420862.2025.2468845 · Cited by 8 · see citing works
Single–amino acid variants in target epitopes can confer resistance to antibody-based therapies
Marone, R., Asllanaj, E., Capoferri, G., Schwede, T. F., Jeker, L. T., & Lepore, R. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ady4877 · Cited by 11 · see citing works
Rawat, P., Sharma, D., Prabakaran, R., Ridha, F., Mohkhedkar, M., Vani, J., & Gromiha, M. M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac439 · Cited by 8 · see citing works
NanoNet: Rapid end-to-end nanobody modeling by deep learning at sub angstrom resolutionPreprint
Cohen, T., Halfon, M., & Schneidman‐Duhovny, D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.03.454917 · Cited by 8 · see citing works
Ramon, A., Ali, M., Atkinson, M., Saturnino, A., Didi, K., Visentin, C., Ricagno, S., Xu, X., Greenig, M., & Sormanni, P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.28.538712 · Cited by 8 · see citing works
Accurate prediction of CDR-H3 loop structures of antibodies with deep learning
Chen, H., Fan, X., Zhu, S., Pei, Y., Zhang, X., Zhang, X., Liu, L., Qian, F., & Tian, B. (2024) · eLife · doi:10.7554/elife.91512 · Cited by 8 · see citing works
“To evaluate the performance of AF2 against currently available methods, we conducted two datasets (DB1 and DB2) with high-resolution ( 2.5 Å) X-ray crystal structures from SAbDab ( Raybould et al., 2020 ).”
MethodInfluentialPD-1 Targeted Antibody Discovery Using AI Protein Diffusion
Ford, C. T. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241275947 · Cited by 7 · see citing works
“Heavy and light chain sequences of 33 PD-1 targeting antibodies (Fv region only) were retrieved from the Therapeutic Structural Antibody Database (Thera-SAbDab) 18 on November 11, 2023.”
MethodRAPID: A Rep-Seq Dataset Analysis Platform With an Integrated Antibody Database
Zhang, Y., Chen, T., Zeng, H., Yang, X., Xu, Q., Zhang, Y., Chen, Y., Wang, M., Zhu, Y., Lan, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717496 · Cited by 7 · see citing works
“The included therapeutic antibodies include 521 antibodies that were recognized by the World Health Organization (WHO) and downloaded from the Therapeutic Structure Antibody Database (Thera-SAbDab) (25).”
BackgroundMethodAdapting ProteinMPNN for antibody design without retrainingPreprint
del Alamo, D., Frick, R., Truan, D., & Karpiak, J. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.09.653228 · Cited by 6 · see citing works
“As a result, the overall designs shared a median of 75% sequence identity with the most similar germline V-genes, far short of the 90% median observed for therapeutic antibodies 15 (Figure 1A).”
The SpyBLI cell-free pipeline for the rapid quantification of binding kinetics from crude samples
Predeina, O., Atkinson, M., Wissett, O., Ali, M., Visentin, C., Ricagno, S., Keeble, A. H., Howarth, M. R., & Sormanni, P. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00079c · Cited by 6 · see citing works
“…region, followed by the T7 promoter, then a 47-nucleotide spacer, which we took from the pDEST E. coli expression vector used to express the SpyCatcher003 protein, and that contains the ribosome binding site, followed by the coding sequence and a short 3 0 -end region of just 10 nucleotides (Fig.”
AntiBMPNN: Structure‐Guided Graph Neural Networks for Precision Antibody Engineering
Sun, Z., Yuan, J., Jaiswal, D., Ge, J., Liang, T., Wei, J., Cao, J., Li, Y., Chu, X., Chen, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202504278 · Cited by 7 · see citing works
SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics
Testa, S., Pal, A., Subramanian, A., Varma, S., Tang, J. P., Graham, D., Arfan, S., Pan, M., Bui, N. Q., Ganjoo, K. N., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01514-9 · Cited by 6 · see citing works
“Specifically, we downloaded a list of clinically developed mAbs, ADCs, scFvs, Fabs, nanobodies, and fusion proteins from Thera-SAbDab [160] (accessed on 07/16/2024), retaining only agents developed for human use, and removing all those agents with clinical development phase reported as “TBC,”…”
Wei, W., & Sulea, T. I. (2024) · mAbs · doi:10.1080/19420862.2024.2404064 · Cited by 6 · see citing works
“15 The full list of Protein Data Bank (PDB) accession codes can be found in the Supplementary Material.”
BackgroundZhou, Y., Liu, W., Luo, C., Huang, Z., Savini, G. S. M., Zhao, L., Wang, R., & Huang, J. (2024) · Methods · doi:10.1016/j.ymeth.2024.11.005 · Cited by 6 · see citing works
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia
Métois, A., Bordeleau, M.-È., Thérêt, L., Hajmirza, A., Moujaber, O., Spinella, J.-F., Chagraoui, J., Mayotte, N., Boivin, I., Audemard, E. O., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00769-z · Cited by 6 · see citing works
“[61] Therapeutic antibody information was extracted from the Thera-SAbDab database (opig.stats.ox.ac.uk/webapps/newsabdab/ther-asabdab) on 23rd of March 2023 [62].”
SITA: Predicting site-specific immunogenicity for therapeutic antibodies
Cun, Y., Ding, H., Mao, T., Wang, Y., Wang, C., Li, J., Li, Z., Hu, M., Cao, Z., & Qiu, T. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101316 · Cited by 6 · see citing works
“Five protein datasets were derived from the Protein Data Bank (PDB) [27] and Thera-SAbDab [28]: (1) the IAb-Ab Dataset which contains 41 Antibody-Antibody complex structures (Fig.”
VDDB: A comprehensive resource and machine learning tool for antiviral drug discovery
Tao, S., Chen, Y., Wu, J., Zhao, D., Cai, H., & Wang, L. (2023) · MedComm – Future Medicine · doi:10.1002/mef2.32 · Cited by 6 · see citing works
- Authors
- Raybould, M. I. J., Marks, C., Lewis, A. P., Shi, J., Bujotzek, A., Taddese, B., & Deane, C. M.
- Affiliations
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- UCB Pharma (United Kingdom) (GB)
- Roche Pharma AG (Germany) (DE)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Deane, Charlotte M
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-26
- Volume
- 48
- Issue
- D1
- Pages
- D383-D388
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC6943036
- OpenAlex
- W2974982237
- Cited by
- 199
- References
- 19
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 41 · 2023: 27 · 2022: 23 · 2021: 19 · 2020: 4 · 2019: 1
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Engineering and Physical Sciences Research Council
- Medical Research Council (EP/L016044/1)
- GlaxoSmithKline plc.
- AstraZeneca plc
- F. Hoffmann-La Roche
- UCB Celltech
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Materials Science › Materials Chemistry › Enzyme Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- therapeutic antibodies, nanobodies, antibody variable domains
- MeSH terms
- Metadata, Antibodies, Clinical Trials as Topic, Humans, User-Computer Interface, Sequence Alignment, Internet, Databases, Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
